Partnering for innovation in animal health
Collaboration with external partners is a fundamental part of our innovation strategy in Animal Health. Learn more about the partners we are looking for.
Search
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance
AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
Boehringer and ZEISS partnership eye diseases
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Boehringer Ingelheim Second Transforming Science Day
World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
Veterinary oncology experts meet in Germany
Veterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, Germany
Odile Bain Memorial Prize 2021
Brilliant early-career scientists in parasitology recognized
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
Rethinking mental health care
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Biostatistics & Data Science
Discover how we use data science methods on clinical trials data to develop patient-led innovations and breakthrough treatments.
Central Data Science
Together with our business and IT colleagues, we develop data science-driven solutions, all the way from ideation to product.
Enjoy the ride
Check out this video about the importance of reflecting on the ‘now’, and all the learning, development, and interactions that have led you there.
Life forward - Boehringer Ingelheim company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
A tool to aid in the prevention of African swine fever
ASF COMBAT is an online management and biosecurity assessment tool aimed at reducing the African swine fever introduction risk level.
Partnering Approach Video 2023
Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.
Boehringer Ingelheim Academy
Find out more about our networking and educational initiative
Immuno-Oncology
We are developing complementary platforms (including, T Cell Engagers, oncolytic viruses, and cancer vaccines), which have the potential to turn cold tumors hot, extending the benefits of immunotherapy to more people.
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
Advance study vaccinating increased milk production
[New ADVANCE study shows vaccinating with Bovela® results in increased milk production
Our-position
Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
FDA Grants Breakthrough Status to Schizophrenia Treatment
Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
Submit Your Opportunity
Information on how to submit a partnering opportunity direct to Boehringer Ingelheim’s Business Development & Licensing team
Ridgefield
Ridgefield is home to the company’s US headquarters. The site serves as a key research center for human pharmaceuticals.
Boehringer Ingelheim Access to Healthcare Strategy 2025
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.